Enzalutamide Expands Prostate Cancer Overall Survival
According to the final results of the phase III PROSPER trial presented at the ASCO20 Virtual Scientific Program during the 2020 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine, the addition of enzalutamide to androgen deprivation therapy significantly prolonged overall survival among men with nonmetastatic castration-resistant prostate cancer. Read more. |
Novel Triple Therapy Improves Multiple Myeloma Outcomes
The initial results of the phase III BOSTON trial presented during the ASCO20 Virtual Scientific Program revealed that once-weekly selinexor, bortezomib, and dexamethasone—compared with twice-weekly bortezomib and dexamethasone—met the primary endpoint, significantly enhancing progression-free survival and overall response rate in patients with multiple myeloma. Read more. |